AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. IMNM
  4. [Form 4] Immunome, Inc. Insider Trading Activity

[Form 4] Immunome, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 filing 鈥� Immunome, Inc. (IMNM) discloses that Chief Business Officer Kinney Horn received a new employee stock-option grant for 161,000 shares on 07/29/2025.

  • Instrument: Non-qualified employee stock option giving the right to buy common stock at an exercise price of $10.60 per share.
  • Vesting: 25 % vests on 07/29/2026; the remaining 75 % vests in equal monthly installments (1鈦�36) thereafter, fully vesting by 07/29/2029.
  • Expiration: 07/28/2035 (10-year term).
  • Post-grant holdings: Horn now beneficially owns 161,000 derivative securities; no common shares were reported in Table I.

No shares were sold or disposed of, so the filing reflects compensation-related equity issuance rather than insider selling. The grant modestly increases the company鈥檚 fully-diluted share count and aligns the officer鈥檚 incentives with long-term shareholder value.

Deposito Modulo 4 鈥� Immunome, Inc. (IMNM) comunica che il Chief Business Officer Kinney Horn ha ricevuto un nuovo premio di opzioni azionarie per dipendenti pari a 161.000 azioni il 29/07/2025.

  • Strumento: Opzione azionaria non qualificata per dipendenti che conferisce il diritto di acquistare azioni ordinarie a un prezzo di esercizio di 10,60 $ per azione.
  • Vesting: 25% matura il 29/07/2026; il restante 75% matura in rate mensili uguali (1/36) successivamente, con maturazione completa entro il 29/07/2029.
  • Scadenza: 28/07/2035 (termine di 10 anni).
  • Detenzioni post-concessione: Horn detiene ora beneficiariamente 161.000 strumenti derivati; nessuna azione ordinaria 猫 stata riportata nella Tabella I.

Non sono state vendute o cedute azioni, quindi il deposito riflette un assegnazione di equity legata alla retribuzione piuttosto che una vendita da parte di un insider. Il premio aumenta moderatamente il numero totale di azioni diluite della societ脿 e allinea gli incentivi del dirigente al valore azionario a lungo termine.

Presentaci贸n del Formulario 4 鈥� Immunome, Inc. (IMNM) revela que el Director Comercial Kinney Horn recibi贸 una nueva concesi贸n de opciones sobre acciones para empleados por 161,000 acciones el 29/07/2025.

  • Instrumento: Opci贸n sobre acciones para empleados no calificada que otorga el derecho a comprar acciones comunes a un precio de ejercicio de $10.60 por acci贸n.
  • Vesting: 25% se consolida el 29/07/2026; el 75% restante se consolida en cuotas mensuales iguales (1/36) despu茅s, complet谩ndose el vesting el 29/07/2029.
  • Vencimiento: 28/07/2035 (plazo de 10 a帽os).
  • Participaciones posteriores a la concesi贸n: Horn posee ahora beneficiariamente 161,000 valores derivados; no se reportaron acciones comunes en la Tabla I.

No se vendieron ni dispusieron acciones, por lo que la presentaci贸n refleja una emisi贸n de acciones relacionada con compensaci贸n en lugar de una venta por parte de un insider. La concesi贸n incrementa modestamente el recuento total diluido de acciones de la empresa y alinea los incentivos del ejecutivo con el valor a largo plazo para los accionistas.

Form 4 鞝滌稖 鈥� Immunome, Inc. (IMNM)電� 斓滉碃靷梾毂呾瀯鞛� Kinney Horn鞚� 2025雲� 7鞗� 29鞚检棎 161,000欤� 鞁犼窚 歆侅洂 鞀ろ啞鞓奠厴 攵�鞐�毳� 氚涭晿鞚岇潉 瓿店皽頃╇媹雼�.

  • 靾橂嫧: 欤茧嫻 $10.60鞚� 頄夓偓臧�瓴╈溂搿� 氤错喌欤茧ゼ 甑Г頃� 甓岆Μ毳� 攵�鞐晿電� 牍勳瀽瓴� 歆侅洂 鞀ろ啞鞓奠厴.
  • 氩犾姢韺�: 25%電� 2026雲� 7鞗� 29鞚检棎 氩犾姢韺呺悩氅�, 雮橂ǜ歆� 75%電� 鞚错泟 毵れ洈 霃欖澕頃� 牍勳湪(1/36)搿� 氩犾姢韺呺悩鞏� 2029雲� 7鞗� 29鞚缄箤歆� 鞕勳爠頌� 氩犾姢韺呺惄雼堧嫟.
  • 毵岆: 2035雲� 7鞗� 28鞚� (10雲� 旮绊暅).
  • 攵�鞐� 頉� 氤挫湢: Horn鞚� 順勳灛 161,000臧滌潣 韺岇儩 歃濌秾鞚� 鞁れ鞝侅溂搿� 靻岇湢頃橁碃 鞛堨溂氅�, 響� I鞐愲姅 氤错喌欤缄皜 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.

欤检嫕 毵る弰雮� 觳橂秳鞚� 鞐嗢棃鞙茧瘈搿� 鞚� 鞝滌稖鞚� 雮措秬鞛� 毵る弰臧� 鞎勲媽 氤挫儊 甏�霠� 欤检嫕 氚滍枆鞚� 氚橃榿頃╇媹雼�. 鞚措矆 攵�鞐姅 須岇偓鞚� 鞕勳爠 頋劃 欤检嫕 靾橂ゼ 靻岉彮 歃濌皜鞁滍偆氅� 鞛勳洂鞚� 鞚胳劶韹半笇毳� 鞛リ赴 欤检＜ 臧�旃橃檧 鞚检箻鞁滍偟雼堧嫟.

D茅p么t du formulaire 4 鈥� Immunome, Inc. (IMNM) r茅v猫le que le Chief Business Officer Kinney Horn a re莽u une nouvelle attribution d鈥檕ptions d鈥檃chat d鈥檃ctions pour employ茅s de 161 000 actions le 29/07/2025.

  • Instrument : Option d鈥檃chat d鈥檃ctions non qualifi茅e donnant le droit d鈥檃cheter des actions ordinaires au prix d鈥檈xercice de 10,60 $ par action.
  • Acquisition des droits : 25 % acqui猫rent le 29/07/2026 ; les 75 % restants s鈥檃cqui猫rent en parts mensuelles 茅gales (1/36) ensuite, avec acquisition compl猫te au 29/07/2029.
  • Expiration : 28/07/2035 (dur茅e de 10 ans).
  • D茅tentions apr猫s attribution : Horn d茅tient d茅sormais b茅n茅ficiairement 161 000 titres d茅riv茅s ; aucune action ordinaire n鈥檃 茅t茅 d茅clar茅e dans le Tableau I.

Aucune action n鈥檃 茅t茅 vendue ou c茅d茅e, donc le d茅p么t refl猫te une 茅mission d鈥檃ctions li茅e 脿 la r茅mun茅ration plut么t qu鈥檜ne vente par un initi茅. L鈥檃ttribution augmente modestement le nombre total d鈥檃ctions dilu茅es de la soci茅t茅 et aligne les incitations du dirigeant sur la cr茅ation de valeur 脿 long terme pour les actionnaires.

Formular 4 Einreichung 鈥� Immunome, Inc. (IMNM) gibt bekannt, dass Chief Business Officer Kinney Horn am 29.07.2025 eine neue Mitarbeiteraktienoptionszuteilung 眉ber 161.000 Aktien erhalten hat.

  • Instrument: Nicht qualifizierte Mitarbeiteraktienoption, die das Recht verleiht, Stammaktien zu einem Aus眉bungspreis von 10,60 $ pro Aktie zu kaufen.
  • Vesting: 25 % werden am 29.07.2026 f盲llig; die restlichen 75 % werden danach in gleichen monatlichen Raten (1/36) f盲llig, vollst盲ndiges Vesting bis zum 29.07.2029.
  • Ablauf: 28.07.2035 (10-Jahres-Laufzeit).
  • Best盲nde nach Gew盲hrung: Horn besitzt nun wirtschaftlich 161.000 derivative Wertpapiere; keine Stammaktien wurden in Tabelle I gemeldet.

Es wurden keine Aktien verkauft oder ver盲u脽ert, daher spiegelt die Einreichung eine verg眉tungsbezogene Aktienzuteilung und keinen Insiderverkauf wider. Die Zuteilung erh枚ht die vollst盲ndig verw盲sserte Aktienanzahl des Unternehmens moderat und richtet die Anreize des Gesch盲ftsf眉hrers auf den langfristigen Aktion盲rswert aus.

Positive
  • Performance-aligned compensation: Options are struck at market price, incentivising value creation before reward.
  • Retention mechanism: Four-year vesting schedule encourages the CBO to remain through 2029.
Negative
  • Potential dilution: 161,000 new options add 鈮�0.6 % to fully-diluted share count.
  • Equity overhang risk: Continued option issuance could pressure future EPS if exercised.

Insights

TL;DR: Large C-suite option grant; incentive-aligned, modest dilution, neutral-to-positive governance signal.

The 161 k option grant (鈮�0.6 % of IMNM鈥檚 ~26 M shares outstanding) is typical for a newly appointed CBO. Strike price of $10.60 sits at-or-above recent trading, creating performance-based upside. Ten-year term and four-year vesting encourage retention through 2029. As no shares were sold or hedged, the transaction is not a bearish liquidity event. Dilution impact is immaterial in the near-term but should be monitored as cumulative equity awards grow. Overall impact: neutral for valuation, slightly positive for incentive alignment.

Deposito Modulo 4 鈥� Immunome, Inc. (IMNM) comunica che il Chief Business Officer Kinney Horn ha ricevuto un nuovo premio di opzioni azionarie per dipendenti pari a 161.000 azioni il 29/07/2025.

  • Strumento: Opzione azionaria non qualificata per dipendenti che conferisce il diritto di acquistare azioni ordinarie a un prezzo di esercizio di 10,60 $ per azione.
  • Vesting: 25% matura il 29/07/2026; il restante 75% matura in rate mensili uguali (1/36) successivamente, con maturazione completa entro il 29/07/2029.
  • Scadenza: 28/07/2035 (termine di 10 anni).
  • Detenzioni post-concessione: Horn detiene ora beneficiariamente 161.000 strumenti derivati; nessuna azione ordinaria 猫 stata riportata nella Tabella I.

Non sono state vendute o cedute azioni, quindi il deposito riflette un assegnazione di equity legata alla retribuzione piuttosto che una vendita da parte di un insider. Il premio aumenta moderatamente il numero totale di azioni diluite della societ脿 e allinea gli incentivi del dirigente al valore azionario a lungo termine.

Presentaci贸n del Formulario 4 鈥� Immunome, Inc. (IMNM) revela que el Director Comercial Kinney Horn recibi贸 una nueva concesi贸n de opciones sobre acciones para empleados por 161,000 acciones el 29/07/2025.

  • Instrumento: Opci贸n sobre acciones para empleados no calificada que otorga el derecho a comprar acciones comunes a un precio de ejercicio de $10.60 por acci贸n.
  • Vesting: 25% se consolida el 29/07/2026; el 75% restante se consolida en cuotas mensuales iguales (1/36) despu茅s, complet谩ndose el vesting el 29/07/2029.
  • Vencimiento: 28/07/2035 (plazo de 10 a帽os).
  • Participaciones posteriores a la concesi贸n: Horn posee ahora beneficiariamente 161,000 valores derivados; no se reportaron acciones comunes en la Tabla I.

No se vendieron ni dispusieron acciones, por lo que la presentaci贸n refleja una emisi贸n de acciones relacionada con compensaci贸n en lugar de una venta por parte de un insider. La concesi贸n incrementa modestamente el recuento total diluido de acciones de la empresa y alinea los incentivos del ejecutivo con el valor a largo plazo para los accionistas.

Form 4 鞝滌稖 鈥� Immunome, Inc. (IMNM)電� 斓滉碃靷梾毂呾瀯鞛� Kinney Horn鞚� 2025雲� 7鞗� 29鞚检棎 161,000欤� 鞁犼窚 歆侅洂 鞀ろ啞鞓奠厴 攵�鞐�毳� 氚涭晿鞚岇潉 瓿店皽頃╇媹雼�.

  • 靾橂嫧: 欤茧嫻 $10.60鞚� 頄夓偓臧�瓴╈溂搿� 氤错喌欤茧ゼ 甑Г頃� 甓岆Μ毳� 攵�鞐晿電� 牍勳瀽瓴� 歆侅洂 鞀ろ啞鞓奠厴.
  • 氩犾姢韺�: 25%電� 2026雲� 7鞗� 29鞚检棎 氩犾姢韺呺悩氅�, 雮橂ǜ歆� 75%電� 鞚错泟 毵れ洈 霃欖澕頃� 牍勳湪(1/36)搿� 氩犾姢韺呺悩鞏� 2029雲� 7鞗� 29鞚缄箤歆� 鞕勳爠頌� 氩犾姢韺呺惄雼堧嫟.
  • 毵岆: 2035雲� 7鞗� 28鞚� (10雲� 旮绊暅).
  • 攵�鞐� 頉� 氤挫湢: Horn鞚� 順勳灛 161,000臧滌潣 韺岇儩 歃濌秾鞚� 鞁れ鞝侅溂搿� 靻岇湢頃橁碃 鞛堨溂氅�, 響� I鞐愲姅 氤错喌欤缄皜 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.

欤检嫕 毵る弰雮� 觳橂秳鞚� 鞐嗢棃鞙茧瘈搿� 鞚� 鞝滌稖鞚� 雮措秬鞛� 毵る弰臧� 鞎勲媽 氤挫儊 甏�霠� 欤检嫕 氚滍枆鞚� 氚橃榿頃╇媹雼�. 鞚措矆 攵�鞐姅 須岇偓鞚� 鞕勳爠 頋劃 欤检嫕 靾橂ゼ 靻岉彮 歃濌皜鞁滍偆氅� 鞛勳洂鞚� 鞚胳劶韹半笇毳� 鞛リ赴 欤检＜ 臧�旃橃檧 鞚检箻鞁滍偟雼堧嫟.

D茅p么t du formulaire 4 鈥� Immunome, Inc. (IMNM) r茅v猫le que le Chief Business Officer Kinney Horn a re莽u une nouvelle attribution d鈥檕ptions d鈥檃chat d鈥檃ctions pour employ茅s de 161 000 actions le 29/07/2025.

  • Instrument : Option d鈥檃chat d鈥檃ctions non qualifi茅e donnant le droit d鈥檃cheter des actions ordinaires au prix d鈥檈xercice de 10,60 $ par action.
  • Acquisition des droits : 25 % acqui猫rent le 29/07/2026 ; les 75 % restants s鈥檃cqui猫rent en parts mensuelles 茅gales (1/36) ensuite, avec acquisition compl猫te au 29/07/2029.
  • Expiration : 28/07/2035 (dur茅e de 10 ans).
  • D茅tentions apr猫s attribution : Horn d茅tient d茅sormais b茅n茅ficiairement 161 000 titres d茅riv茅s ; aucune action ordinaire n鈥檃 茅t茅 d茅clar茅e dans le Tableau I.

Aucune action n鈥檃 茅t茅 vendue ou c茅d茅e, donc le d茅p么t refl猫te une 茅mission d鈥檃ctions li茅e 脿 la r茅mun茅ration plut么t qu鈥檜ne vente par un initi茅. L鈥檃ttribution augmente modestement le nombre total d鈥檃ctions dilu茅es de la soci茅t茅 et aligne les incitations du dirigeant sur la cr茅ation de valeur 脿 long terme pour les actionnaires.

Formular 4 Einreichung 鈥� Immunome, Inc. (IMNM) gibt bekannt, dass Chief Business Officer Kinney Horn am 29.07.2025 eine neue Mitarbeiteraktienoptionszuteilung 眉ber 161.000 Aktien erhalten hat.

  • Instrument: Nicht qualifizierte Mitarbeiteraktienoption, die das Recht verleiht, Stammaktien zu einem Aus眉bungspreis von 10,60 $ pro Aktie zu kaufen.
  • Vesting: 25 % werden am 29.07.2026 f盲llig; die restlichen 75 % werden danach in gleichen monatlichen Raten (1/36) f盲llig, vollst盲ndiges Vesting bis zum 29.07.2029.
  • Ablauf: 28.07.2035 (10-Jahres-Laufzeit).
  • Best盲nde nach Gew盲hrung: Horn besitzt nun wirtschaftlich 161.000 derivative Wertpapiere; keine Stammaktien wurden in Tabelle I gemeldet.

Es wurden keine Aktien verkauft oder ver盲u脽ert, daher spiegelt die Einreichung eine verg眉tungsbezogene Aktienzuteilung und keinen Insiderverkauf wider. Die Zuteilung erh枚ht die vollst盲ndig verw盲sserte Aktienanzahl des Unternehmens moderat und richtet die Anreize des Gesch盲ftsf眉hrers auf den langfristigen Aktion盲rswert aus.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Horn Kinney
(Last) (First) (Middle)
C/O IMMUNOME, INC.
18702 N. CREEK PARKWAY, SUITE 100
(Street)
BOTHELL WA 98011
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF BUSINESS OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
07/29/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy) $10.6 07/29/2025 A 161,000 (1) 07/28/2035 Common Stock 161,000 $0 161,000 D
Explanation of Responses:
1. 25% of the shares subject to the options vest on July 29, 2026, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.
/s/ Sandra Stoneman, Attorney-in-Fact 07/31/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What did Immunome (IMNM) disclose in the latest Form 4?

The company granted Chief Business Officer Kinney Horn 161,000 stock options at a $10.60 strike price on 07/29/2025.

Does the filing involve insider selling of IMNM shares?

No. The transaction is an option grant; no shares were sold or disposed of.

When do the IMNM options vest and expire?

25 % vest on 07/29/2026; the rest vest monthly over 36 months. Expiration is 07/28/2035.

How many shares could be issued if all options are exercised?

Up to 161,000 new common shares, representing roughly 0.6 % of current shares outstanding.

What is the ownership form reported for the options?

They are held directly (D) by the reporting person.
Stock IMNM logo
Immunome Inc

NASDAQ:IMNM

IMNM Rankings

#3860 Ranked by Market Cap
N/A Ranked by Dividends

IMNM Latest News

Aug 1, 2025
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 3, 2025
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 5, 2025
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 22, 2025
Immunome to Present at Upcoming Investor Conferences
May 12, 2025
Immunome Reports First Quarter 2025 Financial Results and Provides Business Update

IMNM Latest SEC Filings

Jul 31, 2025
[Form 4] Immunome, Inc. Insider Trading Activity
Jul 31, 2025
[Form 4] Immunome, Inc. Insider Trading Activity
Jul 31, 2025
[Form 4] Immunome, Inc. Insider Trading Activity
Jul 31, 2025
[Form 4] Immunome, Inc. Insider Trading Activity
Jul 31, 2025
[Form 4] Immunome, Inc. Insider Trading Activity

IMNM Stock Data

935.38M
77.01M
19.27%
62.86%
10.99%
Biotechnology
Pharmaceutical Preparations
United States
BOTHELL